Mental deficiency is the most frequently occurring, yet least understood handicap in children. Even a mild form can lead to social isolation, bullying and require assistance with simple tasks. The most common variety, non-syndromic mental deficiency (NSMD), is defined as affecting an otherwise normal looking child. With few physical clues in affected children to point researchers towards candidates to study, progress in identifying genetic causes of NSMD has been very slow. Yet that is beginning to change.

Jacques L. Michaud, a geneticist at the Sainte-Justine University Hospital Research Center and the Centre of Excellence in Neuromics of the Université de Montréal, has led a multidisciplinary team which has identified mutations in a novel gene in children with NSMD. Their study is published in today’s issue of the New England Journal of Medicine and includes collaborators from McGill University in Canada, the National Institute of Mental Health and the Nathan S Kline Institute in the U.S. and the Université Paris Descartes in France.

“NSMD is a disorder that has many causes,” says Dr. Michaud. “By linking this gene to one kind of NSMD, we better understand the causes and we can work towards a way of identifying and treating this incapacitating condition”.

The identified mutations affect the function of SYNGAP1, a gene that codes for a protein involved in the development and function of the connections between brain cells, also called synapses. The disruption of this gene has been shown to impair memory and learning in mice.

A new approach

Dr. Michaud’s research team hypothesized that new mutations that arise in children - while not present in their parents - may represent a common cause of mental deficiency. “Several observations indicate that new mutations are a frequent cause of neurodevelopmental disorders, but their identification has been difficult because it requires the study of a large fraction of genes, which represents a challenging task,” says Dr. Fadi F. Hamdan, first author of the study.

In order to identify these new mutations, the team took advantage of the platform developed by the Synapse to Diseases consortium, based in Montreal, to study 500 synaptic genes in a group of children with unexplained mental deficiency. The team found that three percent of their subjects had new deleterious mutations in the SYNGAP1 gene.

“This discovery illustrates the power of novel technologies that allow researchers to study hundreds of genes in large groups of individuals, and provides validation for the use of such an approach for the exploration of neurodevelopmental disorders,” says Dr. Guy A. Rouleau, Director of Sainte-Justine Research Center and Head of the Synapse to Diseases consortium.

Impact of the discovery

Children with mutations in SYNGAP1 show strikingly similar forms of NSMD, with delays in their language and mental development and, in some cases, a mild form of epilepsy. Now that these SYNGAP1 mutations have been linked to NSMD, diagnostic tests can be offered to children with NSMD, and adapted strategies of learning can be developed. Moreover, because of the wealth of knowledge about the function of SYNGAP1, it may also be possible to design targeted pharmacological therapies that would aim at improving cognition and associated complications such as epilepsy.

###

Recruitment

Dr. Michaud and his colleagues are continuing to recruit children and adults with unexplained NSMD for their study. “Mental deficiency is a complicated disorder, whose causes we are only now beginning to understand. In this study, we are looking for subjects in whom there is no clear cause,” adds Dr. Michaud. Families interested in participating in the study can contact Dr. Michaud through the web site www. chu-sainte-justine.org/recruitment_deficiency.

About the Study

The article “Mutations in SYNGAP1 in Autosomal Non-Syndromic Mental Retardation,” published in the New England Journal of Medicine, was authored by Fadi F. Hamdan, Julie Gauthier, Dan Spiegelman, Anne Noreau, Yan Yang, Stéphanie Pellerin, Sylvia Dobrzeniecka, Mélanie Côté, Elizabeth Perreault-Linck, Lionel Carmant, Guy D’Anjou, Laurent Mottron, Pierre Drapeau, Claude Marineau, Ronald G. Lafrenière, Jean Claude Lacaille, Guy A. Rouleau and Jacques L. Michaud of the Centre of Excellence in Neuromics of Université de Montréal with the collaboration of Éric Fombonne and Ridha Joober of McGill University; Anjene M. Addington and Judith L. Rapoport of the National Institute of Mental Health, Bethesda, Maryland; Lynn E. Delisi of the Nathan S Kline Institute, Orangeburg, New York;Marie-Odile Krebs and Faycal Mouaffak of the Université Paris Descartes, France.

Partners in Research This study was funded by the Canadian Institutes of Health Research, recruitment of the subjects by the Fonds de la Recherche en Santé Québec, and the Synapse to Diseases (S2D ) project by Genome Canada, Génome Québec and the Université de Montréal. ‘

Source: Nicole Saint-Pierre, Sainte-Justine University Hospital Center

For more information, please contact:
Sylvain-Jacques Desjardins
International press attaché
Université de Montréal
Telephone: 514-343-7593
Email: .(JavaScript must be enabled to view this email address)

Mélanie Dallaire
Communications advisor
Public affairs and communications
Sainte-Justine Hospital
Telephone: 514-345-7707
Email: .(JavaScript must be enabled to view this email address)